-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, K2aEmzxFHjwNuBuHPb7AJQ1eUhAiUnbb0aPzvD8nyV60lhueAe3EzPtNVpAObLaz J6SG0x8i5URbPotyDwhM+Q== 0000950123-10-057923.txt : 20100614 0000950123-10-057923.hdr.sgml : 20100614 20100614160548 ACCESSION NUMBER: 0000950123-10-057923 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100610 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20100614 DATE AS OF CHANGE: 20100614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENOMIC HEALTH INC CENTRAL INDEX KEY: 0001131324 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770552594 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51541 FILM NUMBER: 10894929 BUSINESS ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-556-9300 MAIL ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 8-K 1 f56101e8vk.htm FORM 8-K e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 10, 2010
GENOMIC HEALTH, INC.
(Exact name of registrant as specified in its charter)
         
Delaware   000-51541   77-0552594
(State or Other Jurisdiction of
Incorporation) 		  (Commission File Number)   (I.R.S. Employer
Identification No.)
     
301 Penobscot Drive    
Redwood City, CA   94063
(Address of principal executive offices)   (Zip Code)
(650) 556-9300
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))
 
 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.
     The following actions were taken at the Annual Meeting of Stockholders of Genomic Health, Inc., held on June 10, 2010:
1. The following Directors were elected to serve until the 2011 Annual Meeting or until their successors are duly elected and qualified:
                         
                    Broker  
    For     Withheld     Non-Votes  
Randal W. Scott, Ph.D.
     15,774,354       28,137       3,011,248  
 
                        
Kimberly J. Popovits
     15,778,718       23,773       3,011,248  
 
                        
Julian C. Baker
     15,230,393       572,098       3,011,248  
 
                        
Brook H. Byers
     15,780,948       21,543       3,011,248  
 
                        
Fred E. Cohen, M.D., D.Phil.
     15,779,751       22,740       3,011,248  
 
                        
Samuel D. Colella
     15,780,226       22,265       3,011,248  
 
                        
Ginger L. Graham
     15,654,598       147,893       3,011,248  
 
                        
Randall S. Livingston
     15,779,551       22,940       3,011,248  
 
                        
Woodrow A. Myers, Jr., M.D.
     15,780,751       21,740       3,011,248  
 
                        
2. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2010 fiscal year was approved.
         
For   Against   Abstain
18,765,011
  40,454   8,274

 

 

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     Dated: June 14, 2010
         
  GENOMIC HEALTH, INC.
 		  
  By:   /s/ G. Bradley Cole    
    G. Bradley Cole   
    Chief Operating Officer and Chief Financial Officer   
 

 

-----END PRIVACY-ENHANCED MESSAGE-----